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What do cancer patients mean when they complain of concentration and
memory problems?
A Cull, C Hay, SB Love, M Mackie, E Smets and M Stewart
Imperial Cancer Research Fund, Medical Oncology Unit, Western General Hospital, Edinburgh, UK.
Summary Cognitive function items are increasingly included in quality of life measures, and complaints of
concentration and memory difficulties are often reported by cancer patients. The aim of this study was to
examine the factors influencing patients' level of complaint by comparing subjective reports with objective test
performance of a sample of adult lymphoma patients, disease-free and >6 months after treatment. There was
no significant difference between complainers and non-complainers in sociodemographic or clinical
characteristics or in their performance on standard neuropsychometric tests of concentration and memory.
Those reporting concentration and memory difficulties had significantly higher scores on measures of anxiety,
depression and fatigue. This calls into question the validity of including cognitive function items in self-report
quality of life measures. Patients who report concentration and memory difficulties should be screened for
clinically significant and potentially remediable mood disorder. Objective testing remains the method of choice
for assessing higher mental function.
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In a recent survey of psychosocial problems among a mixed
group of cancer patients (Cull et al., 1995), 49% complained
of cognitive impairment, i.e. problems with concentration
and/or memory, which were rated moderate to severe by
21%. The significance of this incidental finding was difficult
to interpret in such an heterogeneous sample but of sufficient
concern to stimulate further study in a setting in which
transient pharmacological effects could be excluded.
In other patient populations, the ability to process
information under pressure of time (as assessed by the
Paced Auditory Serial Addition Task, PASAT) has proved to
be an important predictor of rehabilitative outcome (Gron-
wall, 1977). It is not clear whether the same holds true in
oncology. Two recent studies (Razavi et al., 1993; van Tulder
et al., 1994) have highlighted rehabilitation problems,
particularly in regard to return to work, among disease-free
lymphoma patients. In the study of van Tulder et al., the
cancer survivors had returned to work but reported poorer
work performance, i.e. decreased efficiency, than healthy
controls. Neither of these rehabilitation studies included
assessment of cognitive function.
Estimates of the prevalence of cognitive difficulties are
likely to vary with the method of assessment. In a prospective
study of newly diagnosed lymphoma patients, performance
on objective memory testing was not significantly different
from general population norms, and was unchanging over
time in spite of the fact that 38% of the patients complained
of at least transient memory impairment, which was
persistent for half of them throughout the period of the
study (Devlen et al., 1987).
Studies in other patient groups have reported a weak
relationship between subjective and objective memory
impairment (Lincoln and Tinson, 1989). It has been
suggested that this low correlation invalidates the use of
questionnaires as measures of memory (Herrmann, 1982).
This calls into question the validity of self-report data on
cognitive function generated from quality of life (QL)
measures in common use in oncology, e.g. the EORTC
QLQ-C30 (Aaronson et al., 1993) and the Rotterdam
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Symptom Checklist (de Haes, 1990). However, an alternative
explanation for the low correlations reported to date may be
that the domains assessed by traditional tests of cognitive
function have little overlap with the everyday experience on
which patients base their self-report (Sunderland et al., 1983).
The Rivermead Behavioural Memory Test (RBMT) (Wilson
et al., 1991) differs from the majority of previously published
memory tests in sampling behaviours characteristic of
everyday life. Lincoln and Tinson (1989) found significant
correlations between performance on this test and the self-
reports of stroke patients.
Anxiety and depression may also be relevant. In a study of
patients with epilepsy, those who complained of memory
problems were significantly more depressed and anxious than
non-complainers (Corcoran and Thompson, 1993). In the
study by Devlen et al. (1987), lymphoma patients who were
anxious or depressed were also more likely to report memory
impairment, although this was not reflected in objective test
scores.
Fatigue may also be important. A study of patients with
chronic fatigue syndrome found that those with high levels of
fatigue performed less well on a memory task even in the
absence of depression (McDonald et al., 1993). Fatigue is a
common complaint among cancer patients during treatment
(Smets et al., 1993) and among Hodgkin's disease patients in
remission (Fobair et al., 1986). Research in fatigue in
oncology is in its infancy, and there is generally a dearth of
adequate assessment materials for measuring fatigue sympto-
matology. The recently developed Multi-dimensional Fatigue
Inventory (MFI) (Smets et al., 1995) offers a promising tool
for its further study, and the Brief Mental Fatigue
Questionnaire (BFMQ) (Bentall et al., 1993) offers the
possibility of comparison with published data. The BFMQ
has been shown to discriminate effectively between chronic
fatigue syndrome (CFS) and muscle disease (i.e. physically
fatigued) patients, although not between CFS and depressed
patients.
In summary, it appears that complaints of concentration
and memory difficulties are common among cancer patients
and may be particularly important in the rehabilitation of
cancer survivors. Although patient self-report data on
cognitive function are integral to quality of life assessment
measures in common use in oncology, it is not clear what
cancer patients mean when they report concentration and
memory problems, i.e. whether subjective complaints mirrorConcentration and memory problems in cancer patients
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objective difficulties or reflect emotional distress or fatigue.
This is particularly important in the rehabilitation setting.
Whereas neurological variables may be inflexible to change,
psychological factors in cognitive dysfunction may be
amenable to intervention.
The aim of this study was to compare subjective
complaints of cognitive difficulties with performance on
appropriate objective tests in a sample of disease-free
lymphoma patients in order to examine the factors that
influence patients' level of complaint.
The specific hypotheses tested were:
(1) that subjective complaints of concentration and memory
correlate poorly with performance on objective testing;
(2) that those who complain of cognitive impairment will
score higher on anxiety, depression and fatigue scales
than those who do not;
(3) that those who complain of cognitive impairment will
report using fewer strategies to assist memory than those
who do not;
(4) that those who complain of cognitive impairment will
report a poorer global quality of life than those who do
not.
Patients and methods
Adult lymphoma patients (Hodgkin's and non-Hodgkin's) in
the Oncology Directorate of the Western General Hospital
Trust who were in remission, i.e. disease-free and off
treatment for a minimum of 6 months, were included in the
study. Patients with a history of CNS involvement, head
injury or cerebrovascular or other intracranial disease were
excluded, as were those with a history of major psychiatric
illness, alcohol or substance abuse. Potentially eligible
patients in remission were identified from the Scotland and
Newcastle Lymphoma Group Register. Subsequent eligibility
was checked with the relevant clinicians and by case note
review.
Information was recorded about patient's sex, age,
educational and occupational status. Data were extracted
from case notes regarding diagnosis, i.e. Hodgkin's vs non-
Hodgkin's lymphomas (HL vs NHL); chemotherapy (none vs
single agent vs combination); intensity of therapy (single
modality/agent vs multimodal or intensive chemotherapy);
total duration of treatment (_ 6 months vs >6 months); and
time since treatment stopped (in months).
Subjective reports
EORTC QLQ-C30 This multidimensional quality of life
instrument (Aaronson et al., 1993) is currently in use as an
outcome measure in national lymphoma trials in Britain.
Two of its scales are of particular relevance to this study:
cognitive functioning and global health status/QL.
Items concerning difficulties with concentration and
memory are scored 1-4 (not at all to very much) and
combined to form the cognitive functioning scale on which
linearly transformed scores ranged from 0 to 100. Overall
health and quality of life are each rated 1-7 (very poor to
excellent) and combined to form a global health status/QL
scale that, with linear transformation, also ranges from 0 to
100. On both of these transformed scales a higher score
represents a better level of functioning.
Hospital Anxiety and Depression Scale (HADS) Zigmond
and Snaith (1983) originally reported anxiety and depression
subscales separately using scores in the range 8-10 to denote
possible cases and >11 to identify probable case-level
disturbance. More recently, HADS has been shown to be
the screening instrument of choice for detecting affective
disorder in disease-free cancer patients (Ibbotson et al., 1994).
In this setting the recommended threshold score of 19 is
applied to the total HADS score (anxiety+ depression).
Multi-Dimensional Fatigue Inventory (MFI) This 20-item
Dutch instrument has been pretested in English in a mixed
group of patients receiving radiotherapy in our department
(Smets et al., 1995a, 1996). It consists offive subscales assessing
general, physical and mental fatigue, reduced activity, and
motivation. Subscale scores are derived by summing scores for
the four constituent items, each scored 1 -5.
Brief Mental Fatigue Questionnaire (BMFQ) Patients are
asked to what extent they have been bothered by each of nine
mental fatigue symptoms, e.g. thinking slowed down, on a
scale from 0 (not at all) to 4 (very much). Responses are
summed to give a total score (Bentall et al., 1993).
Memory aids Patients were also interviewed about the
external aids and internal strategies they employ using the
checklist of memory aids developed by Corcoran and
Thompson (1993).
Objective tests
The National Adult Reading Test (NART) The NART
(Nelson, 1991) consists of 50 phonetically irregular words
which the patient reads aloud. The score obtained for the
number of words read correctly has been shown to provide a
reliable estimate of premorbid intellectual ability in adults
suspected of suffering from intellectual deterioration.
Paced Auditory Serial Addition Task (PASAT) This test
(Gronwall and Sampson, 1974) consists of an audiotaped
random series of digits presented at constant speed, i.e one
number per 2.0 s. The patient is required to add consecutive
pairs of numbers. Concentration is required to perform this
complex information-processing task correctly under the
pressure of time. This brief test has proved to be sensitive
to organic impairment. Scores are derived from the total
number of correct additions in one series of 51 digits
(maximum score=50) and compared with published norms
(Roman et al., 1991). As there is a significant practice effect
from first to second presentation while the subject learns
what the task involves, this test was administered twice and
only the results of the second administration were used in the
analysis.
Rivermead Behavioural Memory Test (RBMT) The RBMT
(Wilson et al., 1991) was developed to detect impairment of
everyday memory function. It consists of 11 items which
involve remembering to carry out some everyday tasks or
retaining the type of information required for adequate
everyday functioning. There are two scoring systems for the
RMBT: a screening score and a standardised profile score.
For the screening score each item is scored pass or fail. For
one item immediate and delayed recall are scored separately,
thus summed screening scores range from 0 to 12. Scores <9
indicate memory impairment. To derive standardised profile
scores each item is scored as 2 (normal), 1 (borderline) or 0
(abnormal). Profile scores range from 0 to 24, where a score
of 0-9 indicates severe impairment, 10 -16 moderate
impairment and 17-21 poor memory; and >22 is regarded
as normal.
Procedure
Eligible patients who could be traced were invited by letter
to take part in the study. Patients not wishing to
participate were invited to respond by indicating on a list
the reason for their decision. Participating patients were
invited to complete the EORTC QLQ-C30, HADS and
MFI and return them with a form giving preferred times
for objective testing. The objective tests, BMFQ and
checklist of memory aids were administered (by CH) in
the hospital.Concentration and memory problems in cancer patients
A Cull et al
1676
Statistical analysis
Comparisons oftwo variables, each with only a few categories
(e.g. sex vs complainer/non-complainer), were by means of
Fisher's exact test. Comparisons oftwo variables in which one
variable has two categories and the other variable has many
(e.g. age vs complainer/non-complainer) were achieved using
the two-sample Mann-Whitney U-test. Scores obtained on
MFI, BMFQ and PASAT were compared with published data
using the two-sample t-test. In comparisons in which both
variables have many categories, Spearman's rank correlation
coefficient (ru) was used. When it was appropriate to do so,
parametric testing was also carried out. In all cases the same
results were found on non-parametric and parametric testing.
Logistic regression was used to determine whether both HADS
and fatigue scores were independent predictors of subjective
complainers ofconcentration and memory difficulties. Multiple
regression was used to determine whether both HADS and
fatigue scores were independent predictors of the EORTC
cognitive functioning scale.
Results
The sample
Of 122 patients contacted, 15 (12%) declined to take part in the
study. Four patients said that they felt too ill, four were well
anddid notwish to bereminded oftheir illness, i.e. by returning
to hospital for tests, three were too busy and four gave no
reason. One hundred and seven (88%) completed the self-
report measures sent to them, but 16 declined to attend for
Table I Sociodemographic and clinical characteristics of the sample
Test group
(n =91)
Mean age (s.d.)
Male:female
Employment
Full-time
Part-time
Other
Education
To age 16
To age 18
Higher education
Diagnosis NHL:HL
Chemotherapy
None
Single agent
Combination
Intensity
Non-intensive
Intensive
Median duration of treatment
Median time since treatment
Range
55 years (15.9)
43:48
31
14
46
30
43
18
36:55
27
11
51
35
53
5 months
n=86
43 months
6-243 months
n=85
testingwithout giving a reason. Objective testdata are therefore
available for 91 patients, i.e. 75% of those contacted.
No significant differences were observed between those
who did (test group) and those who did not (no-test group)
present for psychometric testing with respect to age, sex,
employment, educational status, diagnosis, therapy received
or duration of treatment. The no-test group had been off
treatment for longer, i.e. median 107 vs 43 months (Mann-
Whitney, z =2.1, P=0.03). Sociodemographic and clinical
characteristics of the test group are shown in Table I.
Subjective reports
The no-test group reported better cognitive functioning (CF)
on the EORTC CF scale than the test group (Mann-
Whitney, Z=2.0, P=0.05). In the test group, 27 patients
(30%) reported difficulty in concentrating, rated 3-4 (quite a
bit to very much) by 11 (12%) patients. Forty-seven patients
(52%) reported difficulty remembering things, rated 3-4 by
14 (15%) patients. The test group had a mean score of 72.9
(s.d. = 17.9) on the EORTC Global Health Status/QL scale.
There was no significant difference between the test and no-
test group in global QL scores.
There were no significant differences between the test and
no-test groups on the HADS. Among the patients undergoing
psychometric testing, 13 (14%) scored as probable cases of
anxiety on the HADS (i.e. ) 11) and 12 (13%) as possible
cases (i.e. score 8-10). The mean HAD anxiety score for the
test group was 5.6 (s.d. =4.3). There were two (2%) probable
cases of depression and nine (10%) possible cases using the
same cut-offs, and the mean HADS depression score for the
test group was 3.6 (s.d. = 3.0). The Ibbotson Screening Score,
i.e.> 19, identified nine patients (10%) as showing clinically
significant psychological disturbance.
Subjective reports of fatigue in the test and no-test groups
were similar. Test group scores on the MFI subscales were
compared with published data from 'tired' and 'not tired'
patients in our Radiotherapy Department (Table II).
Scores on the BMFQ in the test group ranged from 0 to
30 with a mean of 7.1 (s.d.= 7.1, n=91). This is similar to the
mean score reported by Bentall et al. (1993) for muscular
dystrophy patients (mean=5.9, t=0.8, d.f.= 118) and
significantly lower than the mean scores obtained by CFS
patients (mean=19.5, t=7.4, d.f.=117, P<0.001) or
depressed patients (mean = 19.8, t = 8.2, d.f. = 119, P<0.001).
Objective tests
Estimated premorbid IQ ranged from 70 to 129 with a mean
of 120 (s.d. = 9.0). Three patients were unable to complete the
PASAT. The mean number of correct responses for the
remaining 88 patients, of mean age 54 years, was 24.7
(s.d. = 10.6). This is significantly poorer than reference data
from a general population sample (Roman et al., 1991), in
which 40 adults aged 33 -55 years obtained a mean score of
38 (s.d.=7.6, t=5.4, d.f.=64, P<0.0001) and 41 adults aged
60 -75 years had a mean score of 31 (s.d. =9.2, t =2.8,
d.f. = 72, P = 0.006).
Fifty-seven patients (63%) from the sample showed
evidence of memory impairment as assessed by a screening
Table II Mean scores (s.d.) on the Mental Fatigue Inventory for the test group with comparative data from radiotherapy patients
(Smets et al., 1996)
Test Tired Not tired
MFI subscales (n =91) (n =44) (n =65)
General fatigue 10.6 (3.9) 21.4a (5.1) 10.4 (6.8)
Physical fatigue 9.8 (4.0) 18.3a (6.3) 10.0 (6.5)
Mental fatigue 8.3 (4.4) 14.4a (8.9) 7.8 (5.8)
Reduced motivation 7.9 (3.4) 15.7a (7.5) 8.4 (5.1)
Reduced activity 8.8 (4.0) 22.0a (6.1) 12.3" (7.8)
aTest group vs tired patients: t-test, 143d.f., P<0.001. bTest group vs not tired patients: t-test, 154d.f., P=0.0003.Concentration and memory problems in cancer patients
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score of 9 on RMBT. Profile scores for those tested showed
45 patients (49%) with poor memory and 24 (26%) with
moderate impairment. One patient was found to have severe
memory impairment.
Comparison ofsubjective complaints and performance on
objective testing
Those who rated their concentration and/or memory
difficulties 3 or 4, i.e. 'quite a bit' or 'very much' on those
items (Q20 and Q25) of the EORTC QLQ-C30, were
designated 'complainers' for the purposes of this study.
Subjective complaints of concentration and memory were
not related to IQ as estimated by the NART. Median IQ
estimates for complainers and non-complainers of concentra-
tion difficulties were 124 and 118 respectively (Mann-
Whitney z = 1.6, P=0.1). Median IQ estimates for complai-
ners and non-complainers of memory problems were 123 and
122 (Mann-Whitney z=0.5, P=0.6) respectively. Scores on
the cognitive functioning scale were not correlated with
NART scores (rs =0.005, n =91, P= 1.0).
PASAT scores for those who complained of concentration
difficulties (median 22, range 0-49, n =11) were not
significantly different (Mann-Whitney z=0.2, P=0.8) from
whose who did not report concentration difficulties (median
24, range 0-47, n=80).
There were no significant differences betwee those who
did, and did not, complain of memory problems in
performance on RMBT. The median profile score for
complainers was 18 (range 14-24, n= 14) and for non-
complainers was 19 (range 9-24, n = 77); Mann-Whitney
z = 0.6, P = 0.5). The median screening scores were 8.5 (range
5-12, n=14) and 9 (range 3-12, n=77; Mann-Whitney
z=0.2, P=0.9) respectively.
Scores on the EORTC cognitive functioning scale were not
correlated with scores on PASAT (r,=0.5, n=88, P=0.7) or
on RMBT (profile: r =0.07, n=91, P=0.5; screening:
r,=0.01, n=91, P=0.9).
The relationship of subjective complaints of cognitive
dysfunction to anxiety, depression andfatigue
The significant differences in scores on anxiety, depression
and fatigue scales between those who did and did not
complain of concentration and memory difficulties are shown
in Table III.
Scores on the EORTC QLQ-C30 cognitive functioning
scale were highly correlated with HADS anxiety and
depression scores, in each case rs=0.5, P<0.0001. Cognitive
functioning scores were significantly correlated with all self-
report scales of fatigue (i.e. MFI general fatigue, rs=0.5,
P<0.0001; MFI physical fatigue, rs=0.3, P=0.007; MFI
reduced activity, rs=0.2, P =0.03; MFI mental fatigue,
rs=0.7, P<0.0001; MFI reduced motivation, rs=0.4,
P=0.0003; BFMQ, rs=0.7, P<0.0001).
The use ofstrategies to improve memory
Those who complained of concentration difficulties on the
EORTC QLQ-C30 used significantly more external memory
Table III Comparison of mean anxiety, depression and fatigue scores for those who do and do not complain of concentration and memory
difficulties
Q20 concentration Q25 memory
Non-complainers Complainersa Non-complainers Complainersa
(n =80) (n = 11) (n= 77) (n= 14)
HAD anxiety
Mean score 4.9 (3.7) 10.1 (5.7)*** 4.7 (3.5) 10.4 (5.2)***
Percentage of cases 23 64 19 71
HAD depression
Mean scores (s.d.) 3.2 (2.7) 6.8 (3.4)*** 2.9 (2.5) 7.4 (3.1)***
Percentage of cases 8 45 5 50
HAD (A+D)
Mean score (s.d.) 8.1 (5.6) 16.9 (8.6)*** 7.6 (5.1) 17.9 (7.6)***
Percentage of cases> 19 9 45 5 57
Mean MFI (s.d.)
General fatigue 10.1 (3.8) 13.8** (3.1) 9.9 (3.7) 14.1*** (2.8)
Physical fatigue 9.7 (4.0) 10.7 (3.8) 9.5 (4.0) 11.7* (3.5)
Reduced activity 8.6 (4.0) 10.3 (4.1) 8.4 (3.8) 10.9* (4.3)
Mental fatigue 7.4 (3.6) 15.5*** (3.1) 7.1 (3.4) 15.2*** (3.2)
Reduced motivation 7.6 (3.3) 9.8* (3.7) 7.5 (3.2) 9.9* (4.0)
BMFQ mean (s.d.) 5.2 (5.0) 20.7 (5.3)*** 4.9 (4.5) 19.3 (6.7)***
aQ20/Q25 of EORTC QLQ-C30 rated 3-4 (quite a bit to very much). *P<0.05, **P<0.01, ***P<0.001.
Table IV Regression analyses of subjective complaints of cognitive impairment
(a) Logistic regression-EORTC concentration/memory item scores
95% confidence
Odds ratio intervals P-value
Concentration
MFI mental fatigue 1.7 1.3-2.3 0.001
HAD depression 6.7 0.8-54.0 0.07
Memory
MFI mental fatigue 2.1 1.3-3.4 0.001
HAD depression 52 3.1 -873.0 0.006
(b) Multiple Regression-EORTC QLQ-C30 cognitive functioning (CF) Scale
CF score =95.5 + 18.7 (HAD 'case' depression)- 3.7 (MFI mental fatigue score).Concentration and memory problems in cancer patients
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aids, e.g. lists (median 5, range 2-7; z= 3.4, P= 0.0006), and
more internal strategies, e.g. alphabetical searching, mental
retracing (median 3, range 1-6; z= 2.6, P= 0.008), than non-
complainers (external aids: median 3, range 0 -6; internal
strategies: median 2, range 0-5).
Similarly, those who complained of memory difficulties
reported using more external aids (median 4, range 2 -6;
z= 3.2, P=0.001) and internal strategies (median 3, range 1-
6; z=2.71, P=0.007) than non-complainers (external aids:
median 3, range 0-7; internal strategies median 2, range 0-
5).
Scores on the cognitive functioning scale were correlated
with the number of external aids (r,=0.49, n=91, P<0.0001)
and internal strategies (r. =0.32, n =91, P=0.002) used to
assist memory.
Cognitive function and quality of life
Complainers and non-complainers of concentration difficul-
ties showed no significant differences in ratings oftheir health
or global QL on the EORTC QLQ-C30 global health status/
QL scale. By contrast, those who complained of memory
problems did have lower scores on the global health status/
QL scale (Mann-Whitney z= 2.4, P =0.02). This difference
was attributable to the complainers' lower rating of their
overall health (Mann-Whitney z =2.6, P=0.01). For the
samples as a whole, scores on the cognitive functioning scale
were correlated with scores on the global health status/QL
scale (r =0.3, n=91, P=0.007).
Who are the complainers?
Univariate analysis showed no significant differences between
complainers and non-complainers of concentration or
memory difficulties in sociodemographic characteristics (age,
sex, employment status, estimated premorbid IQ or educa-
tional level) or in their clinical characteristics (diagnosis,
chemotherapy or not, intensity/duration of treatment, time
since treatment stopped).
Regression analysis was therefore carried out using the
HADS and fatigue scale scores to predict subjective
complaints of concentration and memory difficulties. The
MFI mental fatigue scale and 'caseness' on the HADS
depression scale independently predicted complaints of
concentration and memory difficulties and scores on the
EORTC cognitive functioning scale (Table IV).
Discussion
The EORTC QLQ-C30 is increasingly widely used inter-
nationally as an outcome measure in cancer clinical trials. Its
cognitive functioning scale has not until now been validated
against objective test data. It is, therefore, not clear what
subjective complaints of concentration or memory difficulties
derived from this scale actually mean.
Cancer patients' cognitive function may be compromised
by organic impairment attributable to the disease process or
treatment. These effects may be temporary and reversible;
however, if the cognitive dysfunction complained of is
associated with persistent difficulties in everyday living, this
information deserves greater prominence in the reporting of
treatment outcomes. On the other hand, complaints of
cognitive difficulties may reflect psychological distress or
fatigue, which are recognised as common among cancer
patients. This distinction has important implications for the
type of intervention that should be offered. Techniques may
be taught to try to limit the problems caused by organic
memory impairment, e.g. use of external memory aids, but
mood disturbance is amenable to potentially curative
intervention and warrants direct attention.
Patients treated for Hodgkin's disease and many patients
with non-Hodgkin's lymphoma have an excellent prognosis
in terms of survival, but the quality of their functional
recovery has been called into question (van Tulder, 1994;
Razavi et al., 1993), and cognitive dysfunction may be a
relevant factor. This patient population, therefore, offers the
opportunity to examine the relationship between subjective
complaints of concentration and memory difficulties and
performance on objective testing in a setting in which the
impact of active disease process and transient pharmacolo-
gical effects can be excluded and the issue has clinical
significance for patients' quality of life.
Difficulties were anticipated in tracing and recruiting long-
term cancer survivors for a hospital-based follow-up study.
We were greatly helped by access to the Scotland and
Newcastle Lymphoma Group Register. The response rate
was excellent, with only 12% of those contacted declining to
participate. The reasons given ranged from 'feeling too well'
to 'not feeling well enough', suggesting no systematic
sampling bias in our data. Subjective complaints of
concentration and/or memory difficulties were more com-
mon among those agreeing to undergo testing, and although
the low prevalence of complaints was clinically encouraging
this meant that the study had low power to detect differences
between those who did and did not complain. Replication in
a larger sample is needed.
The mean estimated IQ of those tested was relatively high,
but there was no evidence that the estimated level of
intellectual ability was associated with subjective complaints
of concentration or memory difficulties.
The objective testing procedure was carefully chosen to be
brief and user friendly, to encourage participation and yet to
be sufficiently sensitive to act as a screen for organic
impairment.
Subjective complaints ofmemory problems were compared
with performance on the RBMT, which was specifically
designed to reflect memory skills used in daily life. Scores on
RBMT relate significantly to conventional memory tests but
correlate better with patients' and relatives' reports of
dysfunction than conventional measures (Lincoln and
Tinson, 1989). Subjective complaints of concentration
difficulties were compared with performance on the
PASAT. This test, which requires divided attention,
sustained concentration and efficient information processing,
has been shown to be sensitive to subtle neurocognitive
deficits. In other patient samples PASAT scores have been
found to mirror patients' self-reported difficulties (Johnson et
al., 1994). Patients may have difficulty in distinguishing
problems with information processing/encoding from pro-
blems with information storage or retrieval from memory
and, to allow for this, scores on the EORTC cognitive
function scale as a whole were compared with performance
on both tests. No relationship could be demonstrated in any
of these analyses between patients' self-reported difficulties
and their performance on objective testing. The interpretation
of the meaning of this two-item scale is therefore open to
question. It may be that, to obtain self-report data about
cognitive function that are related to observable performance,
more detailed questions will have to be asked.
Those who complained ofdifficulties with concentration or
memory were significantly more likely to be clinically anxious
or depressed. Of this sample, 10% were identified as probable
cases warranting at least further assessment of their distress.
Complainers of memory problems were more likely to be
identified as probable cases than non-complainers. Evidence
from other patient populations relates both anxiety and
depression to increased memory complaints. Those scoring
>8 on the HADS depression scale were significantly more
likely to complain of concentration and, particularly, memory
difficulties. These data suggest that patients in remission who
report memory or concentration difficulties rated 3 or 4 on
the EORTC scale should be screened for clinically significant
anxiety and/or depression. Effective intervention to relieve
affective disorder might be expected to be accompanied by
improvement in subjectively reported cognitive difficulties.
Subjective reports of concentration and memory difficul-
ties, which were associated with higher fatigue scores andConcentration and memory problems in cancer patients
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multivariate analysis, showed the MFI mental fatigue scale,
in particular, to be an independent predictor of subjective
complaints on the EORTC items. Responses to the EORTC
cognitive functioning scale may, then, be interpreted in terms
of mental fatigue, but current understanding of the basis of
mental fatigue leaves the clinical significance of this
observation in some doubt. There is a generally high
correlation between fatigue scale scores and measures of
anxiety and depression, observable both in this sample and in
the literature (Fobair et al., 1986; Smets et al., 1996).
Whether or not some common underlying physiological
mechanism can be elucidated, this finding further underlines
the importance of assessing patients who complain of
cognitive dysfunction or fatigue for clinically significant and
potentially remediable emotional disturbance.
Contrary to expectations, complainers of concentration
and memory difficulties reported using significantly more aids
to memory, both external aids, e.g. lists, and internal
strategies, e.g. mental retracing, than non-complainers.
Having to use these aids may be viewed as an indicator of
cognitive failure resulting in the observed self-reports of
difficulties. Clinically, it would be wise to check whether these
coping strategies are being used efficiently, but the primary
action to relieve subjectively experienced problems in patients
with no objective evidence of impairment focuses on
addressing anxiety/depression.
As expected, those who reported better cognitive
functioning also reported a better global quality of life.
On objective testing, this sample exhibited evidence of
cognitive dysfunction in that the mean scores on the PASAT
were lower than reference data from an older sample. In
addition, 63% of the sample were identified by the RBMT
screening score as memory impaired. These findings warrant
further exploration.
The key point to emerge from this study is that what
lymphoma patients in remission mean when they complain of
concentration or memory problems on the EORTC QLQ-
C30 cannot be measured on well-validated objective measures
of concentration or memory. Their subjective reports appear
to reflect affective disorder and mental fatigue. While this
finding needs to be replicated in a larger sample of patients
with complaints about their cognitive function and among
those with different disease sites, treatment histories etc., it
does call into question the validity of such a brief cognitive
function scale.
Validity may be improved by the inclusion of additional
items about specific aspects of cognitive function exemplified
in activities of daily living. In other settings, it has been
suggested that patients' subjective reports of their cognitive
function should be collected in diary format and that
relatives'/carers' reports are more reliable (Herrmann, 1982).
Until this can be demonstrated satisfactorily, objective
performance testing remains the method of choice for
assessing higher mental function.
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